3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
2
Myasthenia Gravis
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Hemangioma
2
Breast Neoplasms
2
Spinal Cord Compression
1
Radiation Injuries
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hepatitis
1
Head and Neck Neoplasms
1
Gallstones
1
Esophageal Stenosis
1
Esophageal Neoplasms
1
Common Bile Duct Neoplasms
1
Common Bile Duct Diseases
1
Colorectal Neoplasms
1
Chemical and Drug Induced Liver Injury
1
Carcinoma, Hepatocellular
1
Brain Injuries
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Interventions
Surveys and Questionnaires
114
Exercise
103
Blood Specimen Collection
99
Radiotherapy
67
Gemcitabine
64
Bevacizumab
57
Standard of Care
56
Cisplatin
55
Cyclophosphamide
51
Capecitabine
50
Carboplatin
49
Docetaxel
47
pembrolizumab
46
Dexamethasone
46
Paclitaxel
45
Interviews as Topic
43
Oxaliplatin
40
Magnetic Resonance Spectroscopy
39
Fluorouracil
37
Methods
36
Irinotecan
36
Therapeutics
33
Drug Therapy
33
Radiosurgery
31
Nivolumab
30
Erlotinib Hydrochloride
27
Educational Status
26
Everolimus
24
Leucovorin
23
Control Groups
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms
×
Steroids
×
Clear all
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled